MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
Pharmaceutical Executive
March 3, 2014
Sillup & Porth
Pharm Exec: Annual Press Audit 2014 Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2012
Sillup & Porth
Pharma & The Press Our eighth annual press audit finds the industry out of the crosshairs for now. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2009
Porth & Sillup
Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it. mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2006
Porth & Sillup
Annual Press Audit: Front Page Pharma Newspapers in a study pool published more than twice as many front-page and editorial-page stories on the pharmaceutical industry than they did last year. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2007
Porth & Sillup
Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news. mark for My Articles similar articles
Pharmaceutical Executive
March 1, 2011
Pharm Exec's Seventh Annual Media Audit Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2009
Jill Wechsler
Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs. mark for My Articles similar articles
Chemistry World
March 25, 2010
Rebecca Trager
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2008
Jill Wechsler
Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers. mark for My Articles similar articles
Searcher
October 2010
Stephanie C. Ardito
The Medical Digital: U.S. Healthcare Reform: A Follow-Up For those interested in serious, scholarly research regarding the historical progress of U.S. healthcare reform, this column and my prior column might be a good pairing for neutral sources. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2013
Jill Wechsler
Transformation to Characterize 2013 FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2009
Walter Armstrong
Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges. mark for My Articles similar articles
Pharmaceutical Executive
April 10, 2014
Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler. mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2007
Stan Bernard
Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2012
Jill Wechsler
Obamacare, Innovation and Pricing Tax and budget decisions will shape the healthcare market and drug research and regulation. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2006
Sales and Marketing: Where the Buck Stops Pharma's ultimate customer is the employer - the guy who pays the health plan's bill. Here's what he wants to know about drugs. mark for My Articles similar articles
ONLINE
May/Jun 2003
Hal Kirkwood
Analyze That: LexisNexis Media Analyzer Media Analyzer is a new and interesting company and media database from LexisNexis. Its ability to analyze both textually and graphically how media sources cover companies, sectors, and news topics will find many practical applications in business, communications, and journalism. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2011
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. mark for My Articles similar articles
Pharmaceutical Executive
September 1, 2012
Jill Wechsler
Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare. mark for My Articles similar articles
Nursing Management
April 2011
Deborah E. Trautman
Healthcare Reform: 1 Year Later A year after the Patient Protection and Affordable Care Act was signed into law, the nation remains divided. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2011
Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2012
Jill Wechsler
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2011
Jon Zifferblat
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country mark for My Articles similar articles
The Motley Fool
May 12, 2009
Brian Orelli
Your Company Is Giving Away Revenue Bad news for investors in the health-care industry: the companies you invest in just pledged to give back 1.5% of their expected U.S. revenue growth to President Obama. mark for My Articles similar articles
Pharmaceutical Executive
April 1, 2012
Medical Meetings: Docs Speak Out Three physicians took the stage at the fourth annual West Coast Life Sciences Meeting Management Forum to explain their perspective on healthcare reform, online versus live education, and more. mark for My Articles similar articles
Pharmaceutical Executive
August 1, 2008
Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how. mark for My Articles similar articles
Investment Advisor
July 2009
Melanie Waddell
The Great Health Reform Debate President Barack Obama has set an ambitious deadline of October to achieve comprehensive healthcare reform. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2011
Jill Wechsler
An 'A' for Advancing Expectations As head of both the Food and Drug Administration and the Centers for Medicare and Medicaid Services, Mark McClellan has been at the center of public policy affecting the pharmaceutical industry over the last decade. mark for My Articles similar articles
Reason
April 2008
Ronald Bailey
Medical Speech As a 1997 law expires, the FDA is mulling a plan allowing companies to disseminate unabridged reprints of "truthful and non-misleading" medical journal articles describing "off-label" uses of approved medications to physicians. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2012
William Looney
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2010
Zhu Shen
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda mark for My Articles similar articles
Search Engine Watch
August 2, 2000
Danny Sullivan
Breaking The News Barrier Moreover and Yahoo go a step ordinary news search engines, because they pick up headlines from subject-oriented sites that even news search engines may miss. Those interested in news should try either Moreover or Yahoo, because of the breadth of coverage they offer. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2007
Walter Armstrong
Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2005
Patrick Clinton
PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products. mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2012
Jill Wechsler
Costs and Benefits of Health Reform Will expanded markets and accountable care organizations offset higher rebates, added fees, and closer scrutiny of marketing and prices? mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2006
Chandler & Chicco
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways mark for My Articles similar articles
Pharmaceutical Executive
May 1, 2009
Ad(Ventures) in Pharmaland Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration. mark for My Articles similar articles
Pharmaceutical Executive
July 3, 2007
Humphrey Taylor
Opinion: Lead, Follow, or Get Out of the Way A comparative-effectiveness board is coming. The pharmaceutical industry's wise will embrace the change. mark for My Articles similar articles
Pharmaceutical Executive
December 1, 2010
Jill Wechsler
New Ballgame in Washington Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research mark for My Articles similar articles
The Motley Fool
September 20, 2007
Brian Orelli
Winners and Losers in Universal Health Care Here's a look at the companies that stand to win or lose if Hillary Rodham Clinton is elected -- and gets her three-pronged health-care reform plan through Congress. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2010
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? mark for My Articles similar articles
Pharmaceutical Executive
February 1, 2009
Jill Wechsler
Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths. mark for My Articles similar articles
Pharmaceutical Executive
January 1, 2014
Jill Wechsler
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing mark for My Articles similar articles
Pharmaceutical Executive
June 1, 2005
Zimmerman & Fay
Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole. mark for My Articles similar articles
Pharmaceutical Executive
July 1, 2009
The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets. mark for My Articles similar articles
Pharmaceutical Executive
October 1, 2008
Jill Wechsler
Part D Under Attack Congressional leaders ready campaign to curb Medicare drug plans. mark for My Articles similar articles
Investment Advisor
October 2009
Melanie Waddell
Danger & Opportunity: Healthcare Reform Picks Up Momentum Healthcare reform is still moving ahead, despite opposition from Republicans and well-covered populist discontent over the plan. mark for My Articles similar articles
Pharmaceutical Executive
November 1, 2008
Patrick Clinton
Pharm Exec Q&A: Tommy Thompson The former health secretary offers a reality check on healthcare reform and what to expect in '09. mark for My Articles similar articles
Chemistry World
November 23, 2011
Helen Carmichael
Nanotechnology risks get minimal press coverage A US study has found scant media coverage of the potential risks posed by nanotechnology, with many more articles extolling its future benefits. mark for My Articles similar articles
Pharmaceutical Executive
April 10, 2014
Peter Houston
Fixing Wikipedia Will Pharma join a growing effort to make the world's leading online health information resource more relevant to providers and safer for patients? mark for My Articles similar articles